PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 28(Supplement_5): 53-57
2008
© 2008 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bozkurt, D.
Right arrow Articles by Duman, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bozkurt, D.
Right arrow Articles by Duman, S.

Articles

THE EFFECTS OF COLCHICINE ON THE PROGRESSION AND REGRESSION OF ENCAPSULATING PERITONEAL SCLEROSIS

Devrim Bozkurt1, Selahattin Bicak1, Savas Sipahi1, Huseyin Taskin1, Ender Hur1, Muhittin Ertilav1, Sait Sen2 and Soner Duman1

Departments of Nephrology1 and Pathology,2 Ege University, Izmir, Turkey

Correspondence to: S. Duman, Nefroloji Bilim Dali, Ege Üniversitesi Tip Fakültesi, Bornova 35100, Izmir, Turkey. dumans{at}med.ege.edu.tr; sonerduman{at}hotmail.com

{diamondsuit} Background: Encapsulating peritoneal sclerosis (EPS) is an infrequent but extremely serious complication of long-term peritoneal dialysis. Fibrosis of the submesothelial compact zone and neoangiogenesis underlie the pathophysiology of EPS. Colchicine is a well-known anti-inflammatory and antifibrotic agent that has been used for some fibrosing clinical states, such as liver fibrosis.

{diamondsuit} Objective: To determine the antifibrotic and anti-inflammatory effects of colchicine in an EPS rat model in both progression (P) and regression (R).

{diamondsuit} Methods: 48 nonuremic albino Wistar rats were divided into 5 groups: control group, 2 mL isotonic saline intraperitoneally (IP) daily for 3 weeks; CG group, IP injection of 2 mL/200 g chlorhexidine gluconate (CG) (0.1%) and ethanol (15%) dissolved in saline, daily for 3 weeks; resting group, CG (0 – 3 weeks) + peritoneal resting (4 – 6 weeks); C-R group, CG (0 – 3 weeks) + 1 mg/L colchicine (4 – 6 weeks); C-P group, CG (0 – 3 weeks) + 1 mg/L colchicine in drinking water (0 – 3 weeks). At the end, a 1-hour peritoneal equilibration test was performed with 25 mL 3.86% peritoneal dialysis solution. Dialysate-to-plasma ratio of urea (D/P urea), dialysate WBC count, ultrafiltration volume, and morphological changes of parietal peritoneum were examined.

{diamondsuit} Result: Exposure to CG for 3 weeks resulted in alterations in peritoneal transport (increased D/P urea, decreased ultrafiltration volume; p < 0.05) and morphology (increased inflammation, neovascularization, fibrosis, and peritoneal thickness; p < 0.05). Resting had some beneficial effects on peritoneal derangements; however, once the peritoneum had been stimulated, resting alone was not enough to reverse these pathological changes. Colchicine had more pronounced effects on membrane integrity via decreased inflammation, cell infiltration, and vascularity compared to the resting group.

{diamondsuit} Conclusion: We suggest that colchicine may have therapeutic value in the management of EPS.

KEY WORDS: Encapsulating peritoneal sclerosis; colchicine; rat model; inflammation.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2008 by Multimed Inc.